	US 12,305,237 B2
	CXCR3 as epigenetic marker for the identification of inflammatory immune cells, in particular CD8+ memory t cells
Sven Olek, Berlin (DE); and Josephin Held, Berlin (DE)
Assigned to Precision for Medicine GmbH, Berlin (DE)
Appl. No. 17/054,268
Filed by Precision for Medicine GmbH, Berlin (DE)
PCT Filed May 10, 2019, PCT No. PCT/EP2019/061998 § 371(c)(1), (2) Date Nov. 10, 2020, PCT Pub. No. WO2019/224014, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 10 2018 112 644.1 (DE), filed on May 25, 2018.
Prior Publication US 2021/0230698 A1, Jul. 29, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/154 (2013.01); G01N 2333/7158 (2013.01)]

11 Claims

1. A method for producing an amplicon from a gene region of the human C-X-C motif chemokine receptor 3 (CXCR3) gene, the method comprising:

a) bisulfite treating isolated genomic DNA comprising SEQ ID NO: 1 to generate bisulfite treated DNA, wherein the isolated genomic DNA is from a human cell sample comprising CD8+ memory T cells,

b) producing the amplicon by amplifying from a region of the bisulfite treated DNA comprising SEQ ID NO: 1 prior to bisulfite treatment, and

c) detecting, in the amplicon, TpG at at least one of CpG positions 150, 163, 170, and 184 relative to SEQ ID NO: 1 prior to bisulfite treatment.